Rostislav Christov Raykov Sells 2,431 Shares of Fennec Pharmaceuticals Inc. (TSE:FRX) Stock

Fennec Pharmaceuticals Inc. (TSE:FRX) Director Rostislav Christov Raykov sold 2,431 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of C$6.13, for a total value of C$14,902.03.

Fennec Pharmaceuticals Stock Performance

Fennec Pharmaceuticals stock opened at C$8.16 on Friday. The company has a debt-to-equity ratio of 1,040.68, a current ratio of 6.93 and a quick ratio of 10.17. The stock has a fifty day moving average price of C$10.02 and a two-hundred day moving average price of C$12.44. Fennec Pharmaceuticals Inc. has a 52-week low of C$8.16 and a 52-week high of C$15.43. The firm has a market capitalization of C$222.93 million, a P/E ratio of 163.20 and a beta of 0.46.

Fennec Pharmaceuticals (TSE:FRX) last released its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported C$0.56 earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.67 by C($0.11). Fennec Pharmaceuticals had a negative return on equity of 1,005.59% and a net margin of 6.33%. The company had revenue of C$34.21 million for the quarter, compared to analyst estimates of C$14.19 million. As a group, analysts anticipate that Fennec Pharmaceuticals Inc. will post 1.1958225 EPS for the current fiscal year.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.